Medizinische Hochschule Hannover

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Twincore, Zentrum Fur Experimentelle Und Klinische Infektionsforschung Gmbh

Martin Messerle

Thomas Schulz

Thomas Pietschmann

Hans-Peter Prochnow

Mark Brönstrup

Sibylle Haid

Christine Laqmani-Goffinet

Sergej Franz

Dominic Howard Banda

Penelope Kay-Fedorov

Lars Steinbrück

Ildar Gabaev

Nv Suryanarayana Birudukota

Sebastian Blockus

Thomas F Schulz

The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g. for treating an infectious disease caused by an infection with RSV, KSHV, CMV, DENV, CHIKV, TBEV, VSV, ZIKV and/or HCV.

Labyrinthopeptins as anti-viral agents

The present invention relates to a new binder molecule useful e.g. as an immune suppressor. In particular, it has been recognized that the UL11 protein of human the cytomegalovirus, binds to the CD45 molecule, potentially altering the immune system of an individual. In addition, the present invention relates to binder molecules, in particular, fusion molecules containing the CD45 binding domain of the UL11 protein in combination with a second molecule of interest for delivery of said molecule to cells expressing the CD45 molecule. Moreover, the present invention relates to pharmaceutical compositions comprising the UL11 protein of human cytomegalovirus, or derivatives or homologs thereof, or a nucleic acid sequence encoding the same.

Immune suppressor and its use

Growing community of inventors

Hannover, Germany

Martin Messerle